The UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency, has outlined new guidance aimed at reducing reliance on animal testing and accelerating the adoption of alternative scientific methods in drug development.

The move is part of a broader government-led strategy to modernize preclinical research by promoting the use of innovative technologies such as artificial intelligence, organ-on-a-chip systems, and 3D bioprinted tissues. These alternatives are expected to improve the prediction of drug safety and efficacy while minimizing the need for animal-based studies.

The guidance emphasizes a gradual transition, recognizing that while animal testing remains necessary in certain areas, its use should be reduced wherever validated alternatives exist. Under the roadmap, regulators aim to phase out specific categories of animal testing over the coming years, including skin and eye irritation studies by 2026 and certain toxicity tests by 2027.

To support this transition, the UK government has committed significant funding and infrastructure development to accelerate the validation and regulatory acceptance of non-animal methods. This includes investments in research programs and the establishment of dedicated centers to evaluate and standardize alternative technologies.

The initiative also calls for closer collaboration between regulators, pharmaceutical companies, and research institutions to integrate these new approach methodologies (NAMs) into drug development pipelines. Companies are encouraged to reassess their nonclinical strategies, identify opportunities to incorporate alternative methods, and engage early with regulators to ensure compliance with evolving standards.

Despite the shift, the regulator reiterated that patient safety remains paramount. Animal testing will continue to be used in cases where no scientifically validated alternatives are available, ensuring that safety and efficacy standards are not compromised.

The updated guidance reflects a global trend toward more ethical and scientifically advanced research practices. By promoting innovation and reducing dependence on animal models, the UK aims to position itself as a leader in next-generation drug development while maintaining rigorous regulatory oversight.